Microperimetric changes after intravitreal bevacizumab injection for exudative age‐related macular degeneration
Authors:
Open Access
- 30 January 2012
- journal article
- Published by Wiley in Acta Ophthalmologica
- Vol. 90 (1) , 71-75
Abstract
: Purpose: To evaluate the effect of intravitreal bevacizumab on macular function in the cases of exudative age‐related macular degeneration (AMD).Methods: A total of 21 eyes of 21 patients with exudative AMD were included in this study. In each eye, at baseline and 1, 3 and 6 months after intravitreal bevacizumab injection, logMAR visual acuity, central 4° macular sensitivity, absolute scotoma size, fixation stability and fixation location by MP‐1 microperimetry and optical coherence tomography (OCT) foveal morphologic changes were assessed. After the initial treatment phase which included three consecutive injections, the decision to re‐treat was based on OCT and clinical findings. Subsequent injections could be administered at least 1 month after the previous injection period according to the OCT‐guided treatment regimen.Results: Mean retinal sensitivity within central 4° (12 points) area had increased from 3.69 ± 3.44 dB at baseline to 7.16 ± 3.27 dB at month 6. In all controls after the treatment, there was significant increase in logMAR visual acuity (p < 0.001) and MP‐1 retinal sensitivity (p < 0.001). Mean absolute scotoma in test point location had decreased significantly from 12 of the 76 applied test point locations measured at baseline to five test point locations (−7 test point locations; p < 0.001) at month 6 showing statistical significance. Fixation properties had preserved in all patients 6 months after intravitreal bevacizumab treatment.Conclusion: Intravitreal bevacizumab therapy induced a significant increase in mean retinal sensitivity and significant decrease in mean absolute scotoma size during 6 months. The MP1 microperimetry proved to be a valuable tool in the evaluation of functional benefit of exudative AMD therapy with intravitreal bevacizumab.Keywords
This publication has 20 references indexed in Scilit:
- Intravitreal bevacizumab for treatment‐naïve subfoveal occult choroidal neovascularization in age‐related macular degenerationActa Ophthalmologica, 2009
- A prospective study on intravitreal bevacizumab (Avastin®) for neovascular age‐related macular degeneration of different durationsActa Ophthalmologica, 2008
- Systemic Bevacizumab (Avastin) Therapy for Neovascular Age-Related Macular DegenerationOphthalmology, 2006
- Targeting angiogenesis, the underlying disorder in neovascular age-related macular degenerationCanadian Journal of Ophthalmology, 2005
- Systemic Bevacizumab (Avastin) Therapy for Neovascular Age-Related Macular DegenerationTwelve-Week Results of an Uncontrolled Open-Label Clinical StudyOphthalmology, 2005
- Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancerNature Reviews Drug Discovery, 2004
- Fixation pattern and macular sensitivity in eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration. A microperimetry studySeminars in Ophthalmology, 2004
- Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degenerationOphthalmology, 2003
- Macular degeneration: do conventional measurements of impaired visual function equate with visual disability?British Journal of Ophthalmology, 2000
- Age-Related Macular Degeneration and Blindness due to Neovascular MaculopathyArchives of Ophthalmology (1950), 1984